LBA72 Assessment of clinical and laboratory prognostic factors in patients with cancer and SARS-CoV-2 infection: The COVID-19 and Cancer Consortium (CCC19)

Grivas, Petros; Warner, Jeremy L.; Shyr, Yu; Shah, Dimpy P.; Rubinstein, Sam; Kuderer, N. M.; Choueiri, Toni K.; Rivera, Donna R.; Thompson, Michael A.; Peters, Solange; Desai, Aakash; Khaki, Ali Raza; Pennell, Nathan A.; Hawley, Jessica E.; Halmos, Balázs; Puc, Matthew; Lyman, Gary H.; Rini, Brian I.; Lopes, Gilberto

doi:10.1016/j.annonc.2020.08.2313

Cited by 13 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…► Laboratory variables (eg, low absolute lymphocyte count, high or low absolute neutrophil count, low platelet count, abnormal creatinine, D-dimers, troponin, and C reactive protein). [24][25][26] As discussed previously, completing some non-diseasespecific evaluation, several specific thoracic canceroriented registries or cohort study evaluated the impact of COVID-19 in this specific cancer population.…”

Section: Covid-19 and Cancer Consortium (Ccc-19)mentioning

confidence: 99%

Severity of COVID-19 in patients with lung cancer: evidence and challenges

Passaro

Bestvina

Velez

et al. 2021

J Immunother Cancer

View full text Add to dashboard Cite

Cancer patients are highly vulnerable to SARS-CoV-2 infections due to frequent contacts with the healthcare system, immunocompromised state from cancer or its therapies, supportive medications such as steroids and most importantly their advanced age and comorbidities. Patients with lung cancer have consistently been reported to suffer from an increased risk of death compared with other cancers. This is possibly due to the combination of specific pathophysiological aspects, including underlying pulmonary compromise due to smoking history and the increased specific pressures on respiratory healthcare services caused by the related pandemic. Rationally and safely treating patients with lung cancer during the pandemic has become a continuous challenge over the last year. Deciding whether to offer, modify, postpone or even cancel treatments for this particular patient’s population has become the crucial recurrent dilemma for lung cancer professionals. Chemotherapy, immunotherapy and targeted agents represent distinct risks factors in the context of COVID-19 that should be balanced with the short-term and long-term consequences of delaying cancer care. Despite the rapid and persistent trend of the pandemic, declared by WHO on March 11, 2020, and still ongoing at the time of writing (January 2021), various efforts were made by oncologists worldwide to understand the impact of COVID-19 on patients with cancer. Adapted recommendations of our evidence-based practice guidelines have been developed for all stakeholders. Different small and large-scale registries, such as the COVID-19 and Cancer Consortium (CCC19) and Thoracic Cancers International COVID-19 Collaboration quickly collected data, supporting cancer care decisions under the challenging circumstance created by the COVID-19 pandemic. Several recommendations were developed as guidance for prioritizing the various aspects of lung cancer care in order to mitigate the adverse effects of the COVID-19 healthcare crisis, potentially reducing the morbidity and mortality of our patients from COVID-19 and from cancer. These recommendations helped inform decisions about treatment of established disease, continuation of clinical research and lung cancer screening. In this review, we summarize available evidence regarding the direct and indirect impact of the COVID-19 pandemic on lung cancer care and patients.

show abstract

Section: Covid-19 and Cancer Consortium (Ccc-19)mentioning

confidence: 99%

Severity of COVID-19 in patients with lung cancer: evidence and challenges

Passaro

Bestvina

Velez

et al. 2021

J Immunother Cancer

View full text Add to dashboard Cite

show abstract

“…[141][142][143][144] Additionally, treatment with ICIs has been associated with increased risk of severe COVID-19 respiratory disease in some analyses, but this association was not confirmed in other analyses. [145][146][147][148] The data with regard to BCG treatment is less clear; while some studies indicate that vaccination with BCG (common in regions where tuberculosis infection is a high risk) may be associated with reduced risk of COVID-19, 149 150 further study is still required. Beyond possible impact on outcomes, additional important considerations during the pandemic for patients with cancer include attempts to reduce in-person appointments when possible, use of telemedicine, potential disruptions in public transportation, interruption of clinical trials, and potentially delayed or altered treatment schedules, screening, diagnostic work up, and surveillance.…”

Section: Recognition and Management Of Iraesmentioning

confidence: 99%

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer

Galsky

Balar

Black

et al. 2021

J Immunother Cancer

View full text Add to dashboard Cite

A number of immunotherapies have been developed and adopted for the treatment of urothelial cancer (encompassing cancers arising from the bladder, urethra, or renal pelvis). For these immunotherapies to positively impact patient outcomes, optimal selection of agents and treatment scheduling, especially in conjunction with existing treatment paradigms, is paramount. Immunotherapies also warrant specific and unique considerations regarding patient management, emphasizing both the prompt identification and treatment of potential toxicities. In order to address these issues, the Society for Immunotherapy of Cancer (SITC) convened a panel of experts in the field of immunotherapy for urothelial cancer. The expert panel developed this clinical practice guideline (CPG) to inform healthcare professionals on important aspects of immunotherapeutic treatment for urothelial cancer, including diagnostic testing, treatment planning, immune-related adverse events (irAEs), and patient quality of life (QOL) considerations. The evidence- and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers treating patients with urothelial cancer.

show abstract

“…Selected studies conducted in New York and Northern California have estimated that cancer was present in a minority (5%-6%) of hospitalized COVID-19 patients [8][9][10] ; yet research indicates that cancer in patients diagnosed with COVID-19 is associated with increased risk of severe events (ICU admission, mechanical ventilation, death), with greater risk among patients with metastatic disease, recent treatment (past month) with chemotherapy, immune checkpoint inhibitor therapy (90 days), or surgery. [10][11][12][13][14][15][16][17] Additionally, quicker progression to severe events was found among patients with cancer than among those without cancer. 14,18,19 In the United States, data characterizing COVID-19 in patients with cancer are still quite limited and generally obtained within single health systems or from voluntary surveillance registries or surveys.…”

mentioning

confidence: 95%

Rapid real‐world data analysis of patients with cancer, with and without COVID‐19, across distinct health systems

Hwang

Izano²,

Thompson

et al. 2021

Cancer Reports

View full text Add to dashboard Cite

Background The understanding of the impact of COVID‐19 in patients with cancer is evolving, with need for rapid analysis. Aims This study aims to compare the clinical and demographic characteristics of patients with cancer (with and without COVID‐19) and characterize the clinical outcomes of patients with COVID‐19 and cancer. Methods and Results Real‐world data (RWD) from two health systems were used to identify 146 702 adults diagnosed with cancer between 2015 and 2020; 1267 COVID‐19 cases were identified between February 1 and July 30, 2020. Demographic, clinical, and socioeconomic characteristics were extracted. Incidence of all‐cause mortality, hospitalizations, and invasive respiratory support was assessed between February 1 and August 14, 2020. Among patients with cancer, patients with COVID‐19 were more likely to be Non‐Hispanic black (NHB), have active cancer, have comorbidities, and/or live in zip codes with median household income <$30 000. Patients with COVID‐19 living in lower‐income areas and NHB patients were at greatest risk for hospitalization from pneumonia, fluid and electrolyte disorders, cough, respiratory failure, and acute renal failure and were more likely to receive hydroxychloroquine. All‐cause mortality, hospital admission, and invasive respiratory support were more frequent among patients with cancer and COVID‐19. Male sex, increasing age, living in zip codes with median household income <$30 000, history of pulmonary circulation disorders, and recent treatment with immune checkpoint inhibitors or chemotherapy were associated with greater odds of all‐cause mortality in multivariable logistic regression models. Conclusion RWD can be rapidly leveraged to understand urgent healthcare challenges. Patients with cancer are more vulnerable to COVID‐19 effects, especially in the setting of active cancer and comorbidities, with additional risk observed in NHB patients and those living in zip codes with median household income <$30 000.

show abstract

LBA72 Assessment of clinical and laboratory prognostic factors in patients with cancer and SARS-CoV-2 infection: The COVID-19 and Cancer Consortium (CCC19)

Cited by 13 publications

References 0 publications

Severity of COVID-19 in patients with lung cancer: evidence and challenges

Severity of COVID-19 in patients with lung cancer: evidence and challenges

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer

Rapid real‐world data analysis of patients with cancer, with and without COVID‐19, across distinct health systems

Contact Info

Product

Resources

About